IUCT
IUCT
Toulouse, France5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Site, Stomatognathic Diseases, mouth disorder, neoplasm, oral cavity carcinoma | Recruiting | Phase 3 | 2026-07-22 | NCT06798922 | |
| Second STOP After Pioglitazone Priming in CML Patients | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-07-06 | NCT02889003 | |
| A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 2 | 2026-01-13 | NCT04299646 | |
| Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study | Cognition Disorders, Cognitive Dysfunction, cavernous sinus meningioma, cognitive disorder, psychiatric disorder | Recruiting | Not applicable | 2025-09-29 | NCT05895344 | |
| TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urothelial carcinoma | Recruiting | Phase 2 | 2025-09-22 | NCT04678362 |